Abstract
Antithymocyte globulin (ATG) is traditionally used as a conventional immunosuppression agent in various pathological states including severe aplastic anaemia (SAA), graft versus host disease (GVHD), and for the prevention and treatment of graft rejection and GVHD post bone marrow and liver transplantation. We reviewed the liver functions of 16 haematological patients with no previous liver disorders who received ATG as part of their pre-bone marrow transplantation (BMT) conditioning regimen, and the liver function tests of five SAA patients who received ATG as part of their treatment. Liver functions were evaluated at day — 1 pre-, and days +3 and +10 post-ATG treatment. All patients had normal liver functions before treatment. In the haematological patients, the mean serum lactic dehydrogenase (LDH) levels increased from 408.7 ± 37.7 U/l pre-treatment to 1394.4 ± 488.7 U/l 3 days post-treatment (n = 16;p < 0.029), and then declined to 561.4 ± 61.3 U/l 10 days post-treatment (n = 16;p < 0.043). The mean alanine aminotransferase (ALT) levels increased from 51.9 ± 11.3 U to 184.6 ± 74.6 U (n = 16;p < 0.036), and then declined to 121.9 ± 61.3 U (n = 16; NS). The mean aspartate amino transferase (AST) levels increased from 31.2 ± 5.7 U to 152.0 ± 67.0 U (n = 16;p < 0.44) and then declined to 46.0 ± 14 (n = 16;p < 0.049). The mean r-glutamyltransferase (GTP) levels increased from 93.0 ± 34 to 188.0 ±36 (n = 16;p < 0.02), and were 168.0 ± 37.0 at day +10 (n = 16; NS). The mean bilirubin levels increased from 18.0 ± 1.9μM I-1 to 22.7 ± 2.8 (n = 16); NS), at day +3 and to 31.9 ± 6.9 at day +10 (n = 16; NS). In contrast, no significant changes in liver function tests were demonstrated in the SAA patients treated with ATG. The possible pathophysiologic mechanisms and the clinical implications for liver transplantation are discussed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ticheli, A., Gartwohl, A., Nissen, C. and Speck, B. (1994) Late clonal complication in severe aplastic anemia.Leuk- Lymphoma 12, 167–75.
Paquette, R.L., Tebyani, N., Frane, M.et al. (1995) Long-term outcome of aplastic anemia in adults treated with antithymocyte globulin: comparison with bone marrow transplantation.Blood 85, 283–90.
Deeg, HJ., Loughran, T.P. and Storb, R. (1985) Treatment of human acute graft-versus-host disease with ATG and cyclosporine with or without methylprednisolone.Transplantation 40, 162–6.
Horstman, M., Stockschlader, ML, Kruger, W.et al. (1995) Cyclophosphamide/antithymocyte globulin conditioning of patients with severe aplastic anemia for marrow transplantation from HLA-matched siblings: preliminary results.Ann-Hematol. 71, 77–81.
Bolme, P., Henter, J.I., Winiarski, J.et al. (1995) Allogeneic bone marrow transplantation for hemophagocytic lym-phohistiocytosis in Sweden.Bone Marrow Transplant 15, 331–5.
Kohli-Kumar, Mv Morris, C, DeLaat, C.et al. (1994) Bone marrow transplantation in Fanconi anemia using matched sibling donors.Blood 15, 2050–4.
Li, C.K., Shing, M.K., Chik, K.W. et al. (1996) Bone marrow transplantation in thalassemia patients in Hong Kong — use of GM-CSF. Blood Cell and Bone Marrow Transplants.The Sixth Biennial Sandoz-Keystone Symposium on Bone Marrow Transplantation p.53, Abstr. 246.
Manna, M., Nesci, S., Andreani, M.et al. (1993) Influence of the conditioning regimens on the incidence of mixed chimerism in thalassemic transplanted patients.Bone Marrow Tnmsplant 12 (suppl), 70–3.
Lucarelli, G., Giardini, C. and Baronciani, D. (1995) Bone Marrow Transplantation in thalassemia.Semin.-Hematol. 32, 297–303.
Johnson, F.L., Mentzer, W.C., Kalinyak, K.A., Sullivan, K.M. and Abboud, M.R. (1994) Bone Marrow Transplantation for sickle cell disease. The United States Experience.Am. J. Pediatr. Hematol. Oncol. 16, 22–6.
Keil, F., Kahls, P., Haas, O.A. {eeet al.} (1996) Graft failure after donor leukocyte infusion in relapsed chronic myeloid leukemia: successful treatment with cyclophosphamide and antithymocyte globulin followed by peripheral blood stem cell infusion.Bone Marrow Transplant. 17 (Suppl. 1), S90, Abstr. 404.
Jonas, S., Kling, N., Bechstein, W.O.et al. (1995) Rejection episodes after liver transplantation during primary immunosuppression with FK506 or cyclosporine-based regimen: a controlled perspective randomized trial.Clin.-Transplant. 91, 406–14.
Gomez, Rv Moreno, E. and Colina, F. (1994) OKT/ Antithymocyte globulin immunoprophylaxis in the prevention of acute vanishing bile duct syndrome in retransplanted patients.Transplant. Proc. 26, 3701–5.
Abouna, G.M., al-Abdullah, I.H., Kelly Sullivan, D., Kumar, M.S., Loose, J., Phillips, K., Yost, S. and Serika, D. (1995) Randomized clinical trial of ATG induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring.Transplantation 59, 1564–8.
Whitehead, B., James, L, Helmes, P., Scott, J.P., Smyth, R. and Higenbottam, T.W. (1990) Intensive care management of children following heart and heart-lung transplantation.Intensive-Care-Med. 16, 426–30.
Birkeland, S.A., Beck-Nielsen, H., Rohr, N., Socci, C., Christensen, J. and Dieperink, H. (1995) Islet and kidney transplantation using ATG and cyclosporine monotherapy and a central facility for islet isolation and purification.Transplant Proc. 27, 3150–7.
Berglin, E., Berggren, H., Nilsson, F. and Svensson, S. (1994) Immunosuppression with or without ATG in heart transplantation.Transplant Proc. 26, 1811–2.
Gascon, P., Zoumbos, N.C., Scala, G., Djeu, J.Y., Moore, J.G. and Young, N.S. (1985) Lymphokine abnormalities in aplastic anemia: Implications for the mechanism of action of antithymocyte globulin.Blood 65, 407–13.
Huang, A.T., Mold, N.G. and Zhang, S.F. (1987) Antithymocyte globulin stimulates hematopoietic progenitor cells.Proc. Natl. Acad. Sci. 84, 5942–6.
Doney, K.C., Weiden, P.L., Buckner, CD.et al. (1981) Treatment of severe aplastic anemia using antithymocyte globulin with or without an infusion of HLA haploidentical marrow.Exp. Hematol. 9, 829–34.
Kolb, HJ., Holler, E., Knabe, H., Ledderose, G., Mittermuller, J., Schleuning, M., Mayer, F., Goldman, S.F., Fischer, M., Lorenz, T., Hill, W. and Schuh, R. (1996) Conditioning treatment with ATG modifies GVHD in recipients of marrow from unrelated donors.Bone Marrow Transplant. 17 (Suppl. 1) S10, Abstr. 86.
Bunin, N., Leahey, A., Kamani, N. and August, C. (1996) Bone marrow transplantation in pediatrie patients with severe aplastic anemia: cyclophosphamide and ATG conditioning followed by recombinant human granulocyte macrophage colony stimulating factor.J. Ped. Hematol. Oncol. 18, 68–71.
Nagler, A., Ilan, Y., Amiel, A.et al. (1994) Systemic chimerism in sex-mismatched liver transplant recipients detected by fluorescence in situ hybridization.Transplantation 57, 1458–61.
Rolles, K., Burroughs, A.K., Davidson, B.R., Karatapanism, S., Prentice, H.G. and Hamon, M.D. (1994) Donor-specific bone marrow infusion after orthoptotic liver transplantation.Lancet 29 (343) 263–5.
Cherqui, D., Duvox, C., Charlotte, F.et al. (1994) Value of initial immunosuppression after liver transplantation. Prospective study of 60 cases.Gastroenterol.-Clin.-Biol. 18, 115–22.
Elkashab, M., Reizig, Mv Greig, P.D.et al. (1994) Incidence and patterns of rejection using different induction therapies in liver transplant recipients.Transpl. Proc. 26, 2669–71.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Toren, A., Ilan, Y., Or, R. et al. Impaired liver function tests in patients treated with antithymocyte globulin: Implication for liver transplantation. Med Oncol 14, 125–129 (1997). https://doi.org/10.1007/BF02989638
Issue Date:
DOI: https://doi.org/10.1007/BF02989638